Nexturn Bioscience Co., Ltd. logo

Nexturn Bioscience Co., Ltd. (089140)

Market Closed
11 Aug, 06:30
KRX SM KRX SM
2,390. 00
+70
+3.0172%
40.48B Market Cap
- P/E Ratio
400% Div Yield
42,041 Volume
- Eps
2,320
Previous Close
Add Transaction
Day Range
2,270 2,390
Year Range
1,853 3,250
Want to track 089140 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

089140 closed today higher at ₩2,390, an increase of 3.0172% from yesterday's close, completing a monthly decrease of -6.8226% or -₩175. Over the past 12 months, 089140 stock gained 9.8851%.
089140 pays dividends to its shareholders, with the most recent payment made on Jan 05, 2021.
Nexturn Bioscience Co., Ltd. has completed 4 stock splits, with the recent split occurring on May 04, 2023.
The company's stock is traded on one exchange.

089140 Chart

People also search for

Fine M-Tec Co., Ltd.
8,930
-2.5109%
Genexine Co., Ltd.
2,755
+1.2868%
TiumBio Co., Ltd.
4,950
-1.5905%
GeneOne Life Science Inc.
2,670
0%
Iljin Diamond Co. Ltd.
9,160
0%

Nexturn Bioscience Co., Ltd. (089140) FAQ

What is the stock price today?

The current price is ₩2,390.00.

On which exchange is it traded?

Nexturn Bioscience Co., Ltd. is listed on KRX SM.

What is its stock symbol?

The ticker symbol is 089140.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 400%.

What is its market cap?

As of today, the market cap is 40.48B.

Has Nexturn Bioscience Co., Ltd. ever had a stock split?

Nexturn Bioscience Co., Ltd. had 4 splits and the recent split was on May 04, 2023.

Nexturn Bioscience Co., Ltd. Profile

Biotechnology Industry
Healthcare Sector
- CEO
KRX SM Exchange
- ISIN
South Korea Country
- Employees
- Last Dividend
12 Apr 2023 Last Split
- IPO Date

Overview

Nexturn Bioscience Co., Ltd. stands out as a leading figure within the biotechnology industry, with a primary focus on the development and production of cutting-edge biopharmaceutical products. The firm is renowned for its expertise in the research and manufacturing of pharmaceutical ingredients critical for groundbreaking therapeutic solutions. Nexturn Bioscience's operations are pivotal in generating active compounds essential for various medical treatments, thereby playing an instrumental role in the advancement of healthcare. As an integral component of the pharmaceutical supply chain, the company supports a wide range of clientele, from small biotech startups to large-scale pharmaceutical corporations. Through its dedication to rigorous R&D efforts, Nexturn Bioscience is at the forefront of discovering and refining life-saving drugs and therapies, solidifying its status as a cornerstone in the pursuit of medical progress.

Products and Services

  • Biopharmaceutical Product Development

    Nexturn Bioscience is deeply involved in the development of biopharmaceutical products that target various diseases and conditions. This involves intricate processes of bioengineering, clinical research, and drug formulation to create effective and safe therapeutic options. Their work in this area aims to bridge the gap between scientific discovery and the availability of new treatments in the market, thus addressing unmet healthcare needs.

  • Pharmaceutical Ingredient Manufacturing

    The company excels in the manufacturing of pharmaceutical ingredients, which are crucial for the production of medications. This service encompasses the synthesis, refinement, and commercial production of active pharmaceutical ingredients (APIs) and other critical components required for drug development. Nexturn Bioscience employs state-of-the-art technology and strict quality control measures to ensure that these ingredients meet the highest standards of purity and efficacy.

  • Research and Development (R&D)

    Nexturn Bioscience's R&D initiatives are fundamental to its mission, driving innovation in the biopharmaceutical field. The company invests significantly in research activities to explore new therapeutic areas, improve existing treatment modalities, and develop pioneering drug delivery systems. These efforts contribute to the scientific community's collective understanding and open new avenues for treating diverse medical conditions.

Contact Information

Address: -
Phone: -